Literature DB >> 25052485

Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.

Pooja Singh1, Amita Jain1, Pratima Dixit1, Shantanu Prakash1, Indu Jaiswal1, Vimala Venkatesh1, Mastan Singh1.   

Abstract

The study was done to know the prevalent mutations of gyrA and gyrB genes, and their significance with drug resistance in clinical isolates of Mycobacterium tuberculosis. A total of 100 ofloxacin- (OFX) resistant and 100 OFX-sensitive isolates of M. tuberculosis were consecutively selected from routine Tuberculosis laboratory. Drug resistance pattern of these isolates was recorded. MIC of OFX was tested in all these isolates by absolute concentration method. Quinolone resistance determining region (QRDR) of gyrA and gyrB genes of 320 and 428 bp, respectively, were amplified and sequenced. Sequencing data were analyzed by BLAST on NCBI with reference strain H37Rv. Of 100 OFX-sensitive isolates, 30 were pansusceptible, 28 were monoresistant, 10 were polyresistant and 32 were multidrug resistant (MDR). Among 100 OFX-resistant isolates, 19 were OFX monoresistant, 16 were polyresistant and 65 were MDR. Mutations in gyrA and gyrB genes were observed in 79% and 5% of OFX-resistant isolates, respectively. Most prevalent mutation was found at codon 94 in QRDR of gyrA gene. Double mutations found in gyrA gene and in both gyrA and gyrB genes signifies higher levels of OFX resistance. In one isolate, a substitution at codon 592 (Pro592Ser) was found as a novel mutation outside the QRDR of gyrB gene. Our findings support previous studies that the OFX resistance to M. tuberculosis is associated with mutations in the QRDR of gyrA gene; however, the level of OFX resistance may not be predicted based on the mutation patterns in the gyrA gene.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25052485     DOI: 10.1038/ja.2014.95

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  19 in total

1.  Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China.

Authors:  Xiaomao Yin; Zhaoxian Yu
Journal:  J Infect       Date:  2010-05-07       Impact factor: 6.072

2.  Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates.

Authors:  Florence Brossier; Nicolas Veziris; Alexandra Aubry; Vincent Jarlier; Wladimir Sougakoff
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

3.  Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.

Authors:  G Canetti; W Fox; A Khomenko; H T Mahler; N K Menon; D A Mitchison; N Rist; N A Smelev
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

4.  High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility.

Authors:  Rose Devasia; Amondrea Blackman; Svetlana Eden; Haijing Li; Fernanda Maruri; Ayumi Shintani; Charles Alexander; Anne Kaiga; Charles W Stratton; Jon Warkentin; Yi-Wei Tang; Timothy R Sterling
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

5.  Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China.

Authors:  Jun Chen; Zhifei Chen; Yuanyuan Li; Wei Xia; Xi Chen; Tian Chen; Liping Zhou; Bin Xu; Shunqing Xu
Journal:  Braz J Infect Dis       Date:  2012 Mar-Apr       Impact factor: 1.949

6.  Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey.

Authors:  A N Umubyeyi; L Rigouts; I C Shamputa; K Fissette; Y Elkrim; P W B de Rijk; M J Struelens; F Portaels
Journal:  J Antimicrob Chemother       Date:  2007-02-28       Impact factor: 5.790

7.  Genotypic analysis of isoniazid and rifampin resistance in drug-resistant clinical Mycobacterium tuberculosis complex isolates in southern Turkey.

Authors:  Gonul Aslan; Seda Tezcan; Mehmet Sami Serin; Gurol Emekdas
Journal:  Jpn J Infect Dis       Date:  2008-07       Impact factor: 1.362

8.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

9.  Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.

Authors:  Duy An Duong; Thi Hong Duyen Nguyen; Thi Ngoc Lan Nguyen; Viet Hoa Dai; Thi Minh Ha Dang; Sy Kiet Vo; Dang Anh Thu Do; Van Vinh Chau Nguyen; Huy Dung Nguyen; Ngoc Sy Dinh; Jeremy Farrar; Maxine Caws
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

10.  Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009.

Authors:  Zhenling Cui; Jie Wang; Junmei Lu; Xiaochen Huang; Zhongyi Hu
Journal:  BMC Infect Dis       Date:  2011-03-29       Impact factor: 3.090

View more
  14 in total

Review 1.  SOS response and its regulation on the fluoroquinolone resistance.

Authors:  Ting-Ting Qin; Hai-Quan Kang; Ping Ma; Peng-Peng Li; Lin-Yan Huang; Bing Gu
Journal:  Ann Transl Med       Date:  2015-12

2.  Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.

Authors:  S B Georghiou; M Seifert; D Catanzaro; R S Garfein; F Valafar; V Crudu; C Rodrigues; T C Victor; A Catanzaro; T C Rodwell
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

3.  Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use.

Authors:  Soumitesh Chakravorty; Sandy S Roh; Jennifer Glass; Laura E Smith; Ann Marie Simmons; Kevin Lund; Sergey Lokhov; Xin Liu; Peng Xu; Guolong Zhang; Laura E Via; Qingyu Shen; Xianglin Ruan; Xing Yuan; Hong Zhu Zhu; Ekaterina Viazovkina; Shubhada Shenai; Mazhgan Rowneki; Jong Seok Lee; Clifton E Barry; Qian Gao; David Persing; Robert Kwiatkawoski; Martin Jones; Alexander Gall; David Alland
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

4.  Development and Validation of Multiplex Quantitative PCR Assay for Detection of Helicobacter pylori and Mutations Conferring Resistance to Clarithromycin and Levofloxacin in Gastric Biopsy.

Authors:  Hasyanee Binmaeil; Alfizah Hanafiah; Isa Mohamed Rose; Raja Affendi Raja Ali
Journal:  Infect Drug Resist       Date:  2021-10-06       Impact factor: 4.003

5.  Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.

Authors:  Yingda L Xie; Soumitesh Chakravorty; Derek T Armstrong; Sandra L Hall; Laura E Via; Taeksun Song; Xing Yuan; Xiaoying Mo; Hong Zhu; Peng Xu; Qian Gao; Myungsun Lee; Jongseok Lee; Laura E Smith; Ray Y Chen; Joon Sung Joh; YoungSoo Cho; Xin Liu; Xianglin Ruan; Lili Liang; Nila Dharan; Sang-Nae Cho; Clifton E Barry; Jerrold J Ellner; Susan E Dorman; David Alland
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

6.  Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.

Authors:  Areeya Disratthakit; Therdsak Prammananan; Chanwit Tribuddharat; Iyarit Thaipisuttikul; Norio Doi; Manoon Leechawengwongs; Angkana Chaiprasert
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

7.  Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis.

Authors:  Nele Coeck; Bouke C de Jong; Maren Diels; Pim de Rijk; Elisa Ardizzoni; Armand Van Deun; Leen Rigouts
Journal:  J Antimicrob Chemother       Date:  2016-02-06       Impact factor: 5.790

8.  Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.

Authors:  Xia Yu; Guirong Wang; Suting Chen; Guomei Wei; Yuanyuan Shang; Lingling Dong; Thomas Schön; Danesh Moradigaravand; Julian Parkhill; Sharon J Peacock; Claudio U Köser; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

9.  Genetic Characterization of Second-Line Drug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis from the Northern Region of India.

Authors:  Rakesh Yadav; Aastha Saini; Jureka Mankotia; Rajiv Khaneja; Priyanka Agarwal; Sunil Sethi
Journal:  J Epidemiol Glob Health       Date:  2018-12

10.  Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium tuberculosis clinical isolates in southern China.

Authors:  H M Adnan Hameed; Yaoju Tan; Md Mahmudul Islam; Lingmin Guo; Chiranjibi Chhotaray; Shuai Wang; Zhiyong Liu; Yamin Gao; Shouyong Tan; Wing Wai Yew; Nanshan Zhong; Jianxiong Liu; Tianyu Zhang
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.